Navigation Links
FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
Date:3/8/2010

LAKE ZURICH, Ill., March 8 /PRNewswire/ -- Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3).  Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application.  It is the first and only platelet additive solution now available in America.

In the United States, platelets for transfusion are currently stored in human plasma.  The InterSol® solution from Fenwal is an electrolyte-based formula that replaces a portion of this plasma, which can then be collected and used for other therapeutic purposes, such as treating burn victims.  The FDA clearance allows platelets collected using the Fenwal Amicus® separator system to be stored in a mixture of 65 percent InterSol® solution and 35 percent plasma.

In December, the FDA called approval of the Fenwal InterSol® solution "a significant step in the development and marketing of novel processes for the storage of platelets."(1)  With the new 510(k) clearance, InterSol® solution can now be used for the first time with an approved platelet-collection and storage system.

"We are working closely with the FDA and several blood centers on a post-market study of the InterSol® solution," said William H. Cork, Fenwal chief technology officer and senior vice president.  "Blood centers are eager to implement platelet additive solution, which we can now deliver. This is another important advance from Fenwal."

Platelets are transfused to help prevent or stop bleeding.  They are used to treat trauma victims and cancer patients undergoing chemotherapy.  More than 2 million platelet transfusions take place annually in the United States.

About Fenwal

Fenwal, Inc. is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components.  Fenwal is unique in the depth of its experience and commitment to transfusion medicine.  The company offers the broadest range of products for the automated and manual collection of blood and blood components.  Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories.  Fenwal developed the first flexible, single-use container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components.  Today, the company's products and advanced collection and separation technologies are used to help treat patients on six continents.  Fenwal, Inc. is based in Lake Zurich, Illinois.  For more information, please visit www.fenwalinc.com.

(1) FDA, 2009.  "FDA Approves First Additive Solution for Platelet Storage Up to 5 Days," United States Food and Drug Administration Press Release. [accessed: March 3, 2010] http://www.prnewswire.com/news-releases/fda-approves-first-additive-solution-for-platelet-storage-up-to-5-days-78971167.html.

SOURCE Fenwal, Inc.

Back to top

RELATED LINKS
http://www.fenwalinc.com

'/>"/>

SOURCE Fenwal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
2. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
3. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
4. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
5. FDA Clears a Test for Ovarian Cancer
6. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
7. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
8. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
9. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
10. William Cork Joins Fenwal as Chief Technology Officer
11. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Development, Growth and Demand Forecast to 2022" report to their offering. ... The global wound care ... grow at a CAGR of 6.7% during 2016-2022 Among the ... the largest share in the global market in 2015. Among the various ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental Implants ... ... for Dental Implants in US$ Million. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through 2022. ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software ... announce the opening of a Greenville, South Carolina location. The lab has ... in Greenville. , “We’ve been working with South Carolina clients for years from our ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... Administrative Record, The majority of cases litigated under ERISA involve claims for long-term ...
(Date:3/24/2017)... ... 24, 2017 , ... Judy Buchanan, co-owner of Serenity Natural ... Judy says, “I am passionate about sharing Reiki as a holistic, complementary therapy ... challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical ...
(Date:3/24/2017)... ... 2017 , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: ... life to the fullest, as God intended. “The Adventures of Joey, The Dog Who ... grandmother pursuing her passion for writing, especially about truth and human behavior. , Published ...
Breaking Medicine News(10 mins):